Regarding neurotransmission, MTDLs designed as promising future AD therapeutics may combine anticholinesterase activity with antagonism/inverse agonism toward H3 histamine receptors (H3R) in one molecule, thus affecting cholinergic and histaminergic interneuronal communication [13,23]. The gene discussed is HRH3; the disease is Alzheimer disease.